Liver tumor marker sequences

a marker sequence and liver tumor technology, applied in the field of liver tumor marker sequences, can solve the problems of lack of successful treatment options and no mutational model developed

Inactive Publication Date: 2007-02-22
FARNHAM PEGGY J +2
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No mutational model has yet been developed for liver cancer as it has been for other cancers such as colon cancer.
With no clearly identified cause, successful treatment options are lacking.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liver tumor marker sequences
  • Liver tumor marker sequences
  • Liver tumor marker sequences

Examples

Experimental program
Comparison scheme
Effect test

example

Materials and Methods

[0039] Rapid Amplification of cDNA Ends (RACE). Rapid amplification of cDNA ends (RACE) was performed in both directions using the SMART cDNA amplification kit (Clontech) from mouse liver tumor polyA RNA. 5′ and 3′ RACE were performed using the gene-specific primers, GSP-A [5′-GCATGGCAAGAACAGACTGG-3′] (SEQ ID NO:5) and GSP-B [5′-GGATGAGAAGGGCATCTGGA-3′] (SEQ ID NO:6). 5′ and 3′ RACE products that were identified with the corresponding GSP primer were gel extracted and cloned into TOPO-TA vector (Invitrogen). Cloned products were sequenced by Big Dye (ABI) in the McArdle Laboratory Sequencing Facility (University of Wisconsin-Madison).

[0040] RNA Analysis. For analysis of murine CRG-L2 mRNA, total RNA was extracted from liver using guanidine thiocyanate / CsCl as described previously in (Lukas et al., 1999, incorporated by reference in its entirety). PolyA mRNA was isolated from 250 μg of total RNA using Oligotex mRNA Kit (Qiagen). RT-PCR was performed as describ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
mRNA structureaaaaaaaaaa
Northern blotaaaaaaaaaa
Login to view more

Abstract

Polypeptides whose expression is upregulated in liver tumor cells and cells from liver preneoplastic foci relative to expression in normal liver cells are disclosed as are polynucleotides that encode the polypeptides. In humans, the polynucleotide maps to a region of chromosome 15. The overexpression has also been confirmed in human liver, breast, colon and kidney cancer cell lines. It is believed that the polypeptides are overexpressed in tumor and preneoplastic cells in general.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional application of U.S. application Ser. No. 10 / 620,532 filed on Jul. 16, 2003, which claims the benefit of U.S. provisional application Ser. No. 60 / 396,626, filed on Jul. 17, 2002.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] This invention was made with U.S. Government Support from the following agency: NIH, Grant No. CA22484. The U.S. Government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] Primary liver cancer is the fifth most common cancer worldwide with approximately half a million cases reported in 1990. Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancer and the rates of HCC have increased by over 70% in the last two decades in the U.S. The fatality ratio (mortality / incidence) of liver cancer is approximately 1, indicating that the majority of patients live less than a year. Late diagnosis due to lack of clinical symptoms is one of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68G01N33/574C07H21/04C12P21/06C07K14/82C07K16/30A61K38/00C07K14/47
CPCA61K38/00C07K14/47C07K14/4748G01N33/57438
Inventor FARNHAM, PEGGY J.GRAVEEL, CARRIE R.HARKINS-PERRY, SARAH R.
Owner FARNHAM PEGGY J
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products